Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 5Thoracic 4Head & Neck 3Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Skin Neoplasms 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pioglitazone × Dermatologic × Clear all
NCT02347813 2020-06-23

Preventing Squamous Cell Skin Cancer

University of Rochester

Phase 2 Completed
12 enrolled 10 charts
Dermatologic

Carotid Intimal Medial Thickness 1, Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡